NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02542293,Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE),https://clinicaltrials.gov/study/NCT02542293,NEPTUNE,ACTIVE_NOT_RECRUITING,"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.",YES,Non Small Cell Lung Carcinoma NSCLC,BIOLOGICAL: Durvalumab +Tremelimumab|DRUG: Paclitaxel + carboplatin|DRUG: Gemcitabine + cisplatin|DRUG: Gemcitabine + carboplatin|DRUG: Pemetrexed + cisplatin|DRUG: Pemetrexed + carboplatin,"Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).|OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).","OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets, OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at time of analysis was censored based on last recorded date on which participant was known to be alive.

bTMB ≥16 mut/Mb, bTMB ≥12 mut/Mb and bTMB \<20 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥16 mut/Mb, ≥12 mut/Mb and \<20 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

bTMB non-evaluable analysis set included the subset of participants in FAS whose bTMB status at baseline could not be determined by the GuardantOMNI CDx assay or whose sample was not available.

tTMB analysis sets are defined same as the bTMB analysis sets., From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).|OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets, The OS was defined as time from date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on last recorded date on which participant was known to be alive.

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment. Any participants recruited in China, after global recruitment had ended, were not included in the FAS.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay., From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global or China cohort DCO dates, as applicable (a maximum of approximately 44 months) for each cohort.|Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets, The PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \[RECIST 1.1\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).|PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets, PFS (per RECIST 1.1 using Investigator assessments) was defined as time from date of randomization until date of objective PD or death regardless of whether participant withdrew from randomized therapy or received another anticancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1).

PD-L1-negative analysis set included subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: FAS included all randomized participants prior to end of global recruitment.

China Cohort: China FAS included all randomized participants in China cohort and were used for all China only efficacy analyses.

PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included subset of participants in FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.|Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets, The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) prior to PD.

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay.

tTMB ≥14 mut/Mb, tTMB ≥12 mut/Mb, tTMB ≥10 mut/Mb and tTMB ≥8 mut/Mb analysis sets included the subset of participants in FAS whose tTMB status was ≥14 mut/Mb, ≥12 mut/Mb, ≥10 mut/Mb and ≥8 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).|ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets, The ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with at least 1 visit response of CR or PR prior to PD.

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses.

PD-L1 TC ≥25% and PD-L1 TC ≥50% analysis sets included the subset of participants in the FAS whose PD-L1 status was TC ≥25% and TC ≥50% membrane expression in tumoral tissue, respectively at baseline as defined by the Ventana SP263 PD-L1 Assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.|Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets, DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).|DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets, DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1).

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.|Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets, The APF12 was defined as the percentage of participants who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Tumour scans performed at baseline then every 6 weeks up to 12 months.|APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets, The APF12 was defined as the percentage of patients who were alive and progression free at 12 months from randomization (ie, PFS rate at 12 months).

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses., Tumour scans performed at baseline then every 6 weeks up to 12 months.|Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets, The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global cohort DCO date (approximately 44 months).|PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets, The PFS2 was defined as the time from the date of randomization to the earliest of the progression events subsequent to that used for the primary variable PFS, or death (ie, date of PFS2 event or censoring - date of randomization + 1).

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses., Tumour scans performed at baseline and every 6 weeks up to 48 weeks relative to date of randomization, then every 8 weeks thereafter until confirmed PD/death. Up to Global or China cohort DCO dates, as applicable (approximately 44 months) for each cohort.|OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).

bTMB ≥20 mut/Mb, bTMB ≥16 mut/Mb and bTMB ≥12 mut/Mb analysis sets included the subset of participants in FAS whose bTMB status was ≥20 mut/Mb, ≥16 mut/Mb and ≥12 mut/Mb, respectively at baseline as defined by the GuardantOMNI CDx assay., Months 12, 18 and 24|OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1).

PD-L1-negative analysis set included the subset of participants in FAS whose PD-L1 status was PD-L1-negative at baseline as defined by the Ventana SP263 PD-L1 Assay (ie, \<1% PD-L1-membrane expression in tumoral tissue).

Global Cohort: The FAS included all randomized participants prior to the end of global recruitment.

China Cohort: The China FAS included all randomized participants in the China cohort and were used for all China only efficacy analyses., Months 12, 18 and 24|Serum Concentrations of Durvalumab, Blood samples were collected to determine the serum concentration of durvalumab., Pre-dose and within 1 hour after end of infusion at Week 0 and 12; pre-dose on Week 24 and at follow-up Month 3|Serum Concentrations of Tremelimumab, Blood samples were collected to determine the serum concentration of tremelimumab., Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3|Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive., At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.|Number of Participants With ADA Response to Tremelimumab, Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. ADA prevalence is defined as the percentage of participants with positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA is defined as the sum of treatment-induced ADA and treatment-boosted ADA. ADA incidence is the percentage of participants who were treatment-emergent ADA-positive. Treatment-boosted ADA is defined as baseline positive ADA titer that was boosted to \>=4 fold during the study period. Persistently positive is defined as having at least 2 post baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least 1 post baseline ADA positive measurement and not fulfilling the conditions for persistently positive., At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,953,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,D419AC00003|2015-002197-21,2015-11-03,2020-09-21,2025-12-31,2015-09-07,2022-05-24,2025-01-16,"Research Site, Anaheim, California, 92801, United States|Research Site, San Diego, California, 92123, United States|Research Site, Santa Rosa, California, 95403, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Florham Park, New Jersey, 07932, United States|Research Site, Albuquerque, New Mexico, 87102, United States|Research Site, East Setauket, New York, 11733, United States|Research Site, Fresh Meadows, New York, 11366, United States|Research Site, Poughkeepsie, New York, 12601, United States|Research Site, Stony Brook, New York, 11794, United States|Research Site, Canton, Ohio, 44710, United States|Research Site, Columbus, Ohio, 43219, United States|Research Site, Zanesville, Ohio, 43701, United States|Research Site, Pittsburgh, Pennsylvania, 15212, United States|Research Site, Houston, Texas, 77090, United States|Research Site, Berazategui, B1884BBF, Argentina|Research Site, Buenos Aires, C1025ABI, Argentina|Research Site, Caba, C1426ANZ, Argentina|Research Site, Córdoba, 5000, Argentina|Research Site, La Rioja, 5300, Argentina|Research Site, Rosario, S2000KZE, Argentina|Research Site, San Salvador de Jujuy, 4600, Argentina|Research Site, Santa Rosa, 6300, Argentina|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30110-022, Brazil|Research Site, Belo Horizonte, 30380-472, Brazil|Research Site, Fortaleza, 60336-045, Brazil|Research Site, Ijui, 98700-000, Brazil|Research Site, Itajai, 88301-220, Brazil|Research Site, Porto Alegre, 90035-003, Brazil|Research Site, Porto Alegre, 90160-093, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Sao Paulo, 01221-020, Brazil|Research Site, Sao Paulo, 01246-000, Brazil|Research Site, Sao Paulo, 01323 900, Brazil|Research Site, São José do Rio Preto, 15090-000, Brazil|Research Site, São Paulo, 03102-002, Brazil|Research Site, Plovdiv, 4004, Bulgaria|Research Site, Shumen, 9700, Bulgaria|Research Site, Sofia, 1303, Bulgaria|Research Site, Sofia, 1330, Bulgaria|Research Site, Sofia, 1431, Bulgaria|Research Site, Sofia, 1784, Bulgaria|Research Site, Varna, 9010, Bulgaria|Research Site, Vratza, 3000, Bulgaria|Research Site, Santiago, 7500713, Chile|Research Site, Santiago, 7500921, Chile|Research Site, Santiago, 7520349, Chile|Research Site, Santiago, 8380456, Chile|Research Site, Santiago, 8420383, Chile|Research Site, Temuco, 4810297, Chile|Research Site, Viña del Mar, 2520612, Chile|Research Site, Beijing, 100142, China|Research Site, Changchun, 130000, China|Research Site, Chongqing, 400030, China|Research Site, Guangzhou, 510100, China|Research Site, Hangzhou, 310022, China|Research Site, Shanghai, 200030, China|Research Site, Shanghai, 200032, China|Research Site, Urumqi, 830000, China|Research Site, Wuhan, 430022, China|Research Site, Wuhan, 430030, China|Research Site, Odense C, 5000, Denmark|Research Site, Oulu, FI-90029, Finland|Research Site, Tampere, FI-33521, Finland|Research Site, Athens, 115 22, Greece|Research Site, Athens, 11527, Greece|Research Site, Athens, 14564, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Holargos, Athens, 155 62, Greece|Research Site, Ioannina, 45000, Greece|Research Site, Hong Kong, Hong Kong|Research Site, King's Park, 150001, Hong Kong|Research Site, Shatin, 00000, Hong Kong|Research Site, Ahmedabad, 380016, India|Research Site, Bangalore, 560068, India|Research Site, Bangalore, 560076, India|Research Site, Chennai, 600035, India|Research Site, Gurgaon, 122001, India|Research Site, Karamsad, 388325, India|Research Site, New Delhi, 110 085, India|Research Site, Beer Sheva, 8410101, Israel|Research Site, Jerusalem, 91031, Israel|Research Site, Kfar Saba, 95847, Israel|Research Site, Nahariya, 22100, Israel|Research Site, Petah Tikva, 49100, Israel|Research Site, Ramat Gan, 5265601, Israel|Research Site, Bunkyo-ku, 160-0023, Japan|Research Site, Fukushima-shi, 960-1295, Japan|Research Site, Habikino-shi, 583-8588, Japan|Research Site, Hirosaki-shi, 036-8545, Japan|Research Site, Iizuka-shi, 820-8505, Japan|Research Site, Iwakuni-shi, 740-8510, Japan|Research Site, Kanazawa, 920-8641, Japan|Research Site, Kishiwada-shi, 596-8501, Japan|Research Site, Kobe-shi, 650-0047, Japan|Research Site, Kurume-shi, 830-0011, Japan|Research Site, Kyoto-shi, 607-8062, Japan|Research Site, Mitaka-shi, 181-8611, Japan|Research Site, Nagaoka-shi, 940-2085, Japan|Research Site, Nagoya-shi, 460-0001, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Niigata-shi, 951-8566, Japan|Research Site, Okayama-shi, 700-8607, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Saga-shi, 840-8571, Japan|Research Site, Sagamihara-shi, 252-0375, Japan|Research Site, Sakai-shi, 591-8555, Japan|Research Site, Sendai-shi, 980-0873, Japan|Research Site, Tokushima-shi, 770-8503, Japan|Research Site, Ube-shi, 755-0241, Japan|Research Site, Wakayama-shi, 641-8510, Japan|Research Site, Yokohama-shi, 236-0004, Japan|Research Site, Yokohama-shi, 241-8515, Japan|Research Site, Daegu, 41404, Korea, Republic of|Research Site, Hwasun-gun, 58128, Korea, Republic of|Research Site, Seoul, 05030, Korea, Republic of|Research Site, Seoul, 06273, Korea, Republic of|Research Site, Seoul, 08308, Korea, Republic of|Research Site, Kuala Lumpur, 59100, Malaysia|Research Site, Kuantan, 25100, Malaysia|Research Site, Kuching, 93586, Malaysia|Research Site, Acapulco, 39670, Mexico|Research Site, Aguascalientes, 20020, Mexico|Research Site, Mexico, 14080, Mexico|Research Site, Monterrey, 64710, Mexico|Research Site, Mérida, 97134, Mexico|Research Site, México, 06100, Mexico|Research Site, Arequipa, AREQUIPA01, Peru|Research Site, Bellavista, CALLAO 2, Peru|Research Site, Lima, 15033, Peru|Research Site, Lima, 41, Peru|Research Site, Lima, L27, Peru|Research Site, Lima, LIMA 34, Peru|Research Site, Lima, LIMA 41, Peru|Research Site, Baguio City, 2600, Philippines|Research Site, Cebu, 6000, Philippines|Research Site, Las Pinas City, PH-1704, Philippines|Research Site, Manila, 1000, Philippines|Research Site, Manila, 1003, Philippines|Research Site, Quezon City, 1112, Philippines|Research Site, Bydgoszcz, 85-796, Poland|Research Site, Kielce, 25-734, Poland|Research Site, Kraków, 31-202, Poland|Research Site, Mrozy, 05-320, Poland|Research Site, Olsztyn, 10-357, Poland|Research Site, Poznan, 60-569, Poland|Research Site, Poznań, 60-569, Poland|Research Site, Warszawa, 01-138, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Wodzisław Śląski, 44-300, Poland|Research Site, Łódź, 93-513, Poland|Research Site, Amadora, 2720-276, Portugal|Research Site, Lisboa, 1500-650, Portugal|Research Site, Porto, 4099-001, Portugal|Research Site, Porto, 4100-180, Portugal|Research Site, Porto, 4200-319, Portugal|Research Site, Doha, P.O. Box 3050, Qatar|Research Site, Suceava, 720237, Romania|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115280, Russian Federation|Research Site, Moscow, 125367, Russian Federation|Research Site, Omsk, 644013, Russian Federation|Research Site, Saint Petersburg, 197022, Russian Federation|Research Site, Saint Petersburg, 197342, Russian Federation|Research Site, Saint-Petersburg, 194291, Russian Federation|Research Site, Saint-Petersburg, 197183, Russian Federation|Research Site, St. Petersburg, 197758, Russian Federation|Research Site, Dammam, 31444, Saudi Arabia|Research Site, Riyadh, 11426, Saudi Arabia|Research Site, Riyadh, 12372, Saudi Arabia|Research Site, Singapore, 119228, Singapore|Research Site, Singapore, 217562, Singapore|Research Site, Singapore, 258499, Singapore|Research Site, Singapore, 308433, Singapore|Research Site, Eskilstuna, 63188, Sweden|Research Site, Linköping, 581 85, Sweden|Research Site, Stockholm, 171 64, Sweden|Research Site, Uppsala, 751 85, Sweden|Research Site, Adana, 01120, Turkey|Research Site, Ankara, 06200, Turkey|Research Site, Ankara, 06230, Turkey|Research Site, Ankara, 06280, Turkey|Research Site, Ankara, 6500, Turkey|Research Site, Istanbul, 31755, Turkey|Research Site, Istanbul, 34030, Turkey|Research Site, Istanbul, 34349, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Chernivtsі, 58013, Ukraine|Research Site, Dnipro, 49102, Ukraine|Research Site, Ivano-Frankivsk, 76018, Ukraine|Research Site, Kapitanivka Village, 08111, Ukraine|Research Site, Kharkiv Region, 61070, Ukraine|Research Site, Kirovohrad, 25006, Ukraine|Research Site, Kyiv, 03115, Ukraine|Research Site, Kyiv, 04107, Ukraine|Research Site, Lviv, 79031, Ukraine|Research Site, Lyutizh, 07352, Ukraine|Research Site, Odesa, 65055, Ukraine|Research Site, Sumy, 40022, Ukraine|Research Site, Uzhhorod, 88000, Ukraine|Research Site, Vinnytsia, 21029, Ukraine|Research Site, Guildford, United Kingdom|Research Site, London, EC1M 6BQ, United Kingdom|Research Site, London, NW1 2PG, United Kingdom|Research Site, London, W6 8RF, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Nottingham, NG5 1PB, United Kingdom|Research Site, Taunton, TA1 5DA, United Kingdom|Research Site, Wirral, CH63 4JY, United Kingdom|Research Site, Wolverhampton, WV10 0QP, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/93/NCT02542293/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/93/NCT02542293/SAP_001.pdf"
